Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seaside Therapeutics, Inc.
Age
5–11
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Molecular documentation of the full FMR1 mutation
Current pharmacological treatment regimen has been stable for at least 4 weeks prior to Screening.
Subjects with a history of seizure disorder must currently be receiving treatment with antiepileptics and must have been seizure free for 6 months, or must be seizure free for 3 years if not currently receiving antiepileptics.
If the subject is already receiving stable non-pharmacologic educational, behavioral, and/or dietary interventions, participation in these programs must have been continuous during the 2 months prior to Screening
You may not be if
Subjects with any condition, including alcohol and drug abuse, which might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being.
Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study.
Subjects who have taken another investigational drug within the last 30 days.
Subjects who are not able to take oral medications
Clareo Health | Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
